We Partner Where It Creates Real Value
We partner selectively with pharma and biotech teams where a collaboration creates something neither party would build alone.
What we bring
- CB-101 in multiple myeloma, IND-enabling — our most advanced internal programme
- CB-102 in solid tumours and CB-201 in I&I, in lead optimisation
- FORGE: functionally validated, escape-resistant multispecific TCE design
- Drug development, immunology, and ML infrastructure that scales across disease areas
Partnership types
- Named Programme Partnerships — Co-development on CB-101 or CB-102. A partner brings clinical infrastructure or KOL depth; we bring the programme and platform.
- New Programme Creation — Building new multispecific programmes in agreed therapeutic areas, structured as full co-development from the start.
- Strategic Alliance — A broader collaboration where long-term scientific and commercial alignment makes a closer relationship the right structure. We do not take on commodity antibody engineering.